Tilray Brands (NASDAQ:TLRY) Trading Down 1% – Here’s Why

Tilray Brands, Inc. (NASDAQ:TLRY)’s share price fell 1% during trading on Thursday . The stock traded as low as $6.46 and last traded at $6.66. 2,352,415 shares traded hands during mid-day trading, a decline of 38% from the average session volume of 3,778,870 shares. The stock had previously closed at $6.73.

Trending Headlines about Tilray Brands

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Tilray Medical announced its largest medical cannabis portfolio expansion in Australia to date — this strengthens Tilray’s commercial footprint in a regulated market, could boost recurring medical revenue and improves patient access in a growth market. Tilray Medical Australia Expansion
• Positive Sentiment: Breckenridge Distillery (a Tilray spirits brand) expanded distribution via a Cheba Hut partnership across 18 Colorado locations — smaller consumer distribution wins can help brand awareness and incremental beverage alcohol sales. Breckenridge Distillery Cheba Hut Partnership
• Neutral Sentiment: CEO Irwin Simon told Just Drinks the company must “put stability in place” for BrewDog — signals management focus on integration, cost control and stabilizing margins, but timing and impact on cash flow remain unclear. Tilray CEO on BrewDog Interview
• Neutral Sentiment: The Aveanna Healthcare (AVAH) earnings story and a separate Green Thumb (GTBIF) sector note appeared in your feed but are unrelated to Tilray’s fundamentals — keep focused on TLRY‑specific operational and regulatory catalysts. Aveanna Healthcare Article GTBIF Article
• Negative Sentiment: Technical analysis flagged by Invezz says Tilray “lost a key support” and implies a potential drop toward $5 — this kind of chart‑based sell signal can accelerate short‑term downside as traders react. Invezz Technical Warning
• Negative Sentiment: Market headlines and data providers reported TLRY lagging the market with a multi‑percent intraday decline — confirms short‑term selling pressure and weak sentiment. Yahoo Market Drop Zacks Coverage
• Negative Sentiment: A bearish opinion piece advised avoiding TLRY — headlines like this can influence retail sentiment and add downward pressure on the stock even if they’re qualitative. Motley Fool Negative Take

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Canaccord Genuity Group assumed coverage on Tilray Brands in a research report on Tuesday, January 27th. They set a “hold” rating on the stock. ATB Cormark Capital Markets raised Tilray Brands from a “strong sell” rating to a “hold” rating in a research note on Wednesday, December 10th. Roth Mkm dropped their target price on Tilray Brands from $20.00 to $10.00 and set a “neutral” rating on the stock in a report on Tuesday, January 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tilray Brands in a research report on Wednesday, January 21st. Finally, Wall Street Zen downgraded shares of Tilray Brands from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. One investment analyst has rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $13.33.

Tilray Brands Trading Down 1.0%

The stock has a market cap of $775.96 million, a price-to-earnings ratio of -0.30 and a beta of 1.96. The company has a quick ratio of 1.72, a current ratio of 2.81 and a debt-to-equity ratio of 0.19. The business has a 50-day moving average of $7.94 and a 200-day moving average of $10.62.

Tilray Brands (NASDAQ:TLRY) last issued its earnings results on Thursday, January 8th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.12. Tilray Brands had a negative return on equity of 6.35% and a negative net margin of 251.69%.The company had revenue of $217.51 million for the quarter, compared to analyst estimates of $211.15 million. During the same period in the prior year, the firm posted ($0.03) EPS. As a group, research analysts forecast that Tilray Brands, Inc. will post -0.2 earnings per share for the current year.

Hedge Funds Weigh In On Tilray Brands

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TLRY. Silverlake Wealth Management LLC acquired a new stake in Tilray Brands in the third quarter valued at approximately $25,000. Oppenheimer & Co. Inc. acquired a new position in shares of Tilray Brands during the 3rd quarter worth $25,000. Unified Investment Management acquired a new position in shares of Tilray Brands during the 3rd quarter worth $26,000. J.W. Cole Advisors Inc. raised its holdings in shares of Tilray Brands by 203.2% during the 2nd quarter. J.W. Cole Advisors Inc. now owns 71,890 shares of the company’s stock valued at $30,000 after purchasing an additional 48,177 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Tilray Brands in the 3rd quarter valued at $30,000. Institutional investors own 9.35% of the company’s stock.

Tilray Brands Company Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.